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The Dose of Growth Factors Influences the Synergistic
Effect of Vascular Endothelial Growth Factor
on Bone Morphogenetic Protein 4–Induced
Ectopic Bone Formation
Guangheng Li, M.D., Ph.D.,1 Karin Corsi-Payne, Ph.D.,1 Bo Zheng, M.D.,1 Arvydas Usas, M.D.,1
Hairong Peng, M.D., Ph.D.,2 and Johnny Huard, Ph.D.1
Although vascular endothelial growth factor (VEGF) has been shown to act synergistically with bone morpho-
genetic protein (BMP)2 and BMP4 to promote ectopic endochondral bone formation via cell-based BMP gene
therapy, the optimal ratio of VEGF to either of the BMPs required to obtain this beneficial effect remains unclear. In
the current study, two cell types (C2C12, NIH=3T3) were retrovirally transduced to express BMP4 only or both
BMP4 and VEGF. The resulting groups of cells were tested for their cellular proliferation, in vitro mineralization
capacity, survival potential, and ability to undergo ectopic bone formation when implanted into a gluteofemoral
muscle pocket created in severe combined immunodeficient mice. Results showed that VEGF inhibited the in vitro
calcification of C2C12 and NIH=3T3 cells transduced to express BMP4. In vivo, C2C12 and NIH=3T3 cells ex-
pressing BMP4 and VEGF displayed significantly less bone formation than the same cells expressing only BMP4.
In vivo, our results indicated that, when the ratio of VEGF to BMP4 is high, a detrimental effect on ectopic bone
formation is observed; however, when the ratio is kept low and constant over time, the detrimental effect that
VEGF has on ectopic bone formation is lost. Our studies revealed that VEGF’s synergistic role in BMP4 induced
ectopic bone formation is dose and cell-type dependent, which is an important consideration for cell-based gene
therapy and tissue engineering for bone healing.
Introduction
Endochondral bone formation begins as a mesenchy-mal condensation, which then undergoes cartilage for-
mation and cartilage resorption, coupled with blood vessel
invasion and ultimately bone formation. Vascular endothelial
growth factor (VEGF) is involved in all of the above steps,
which are known to occur during embryonic development of
long bones and the healing of bone fractures.1–4 The essential
role of VEGF for the survival of chondrocytes during em-
bryogenesis has been shown using a VEGF knockout mouse
model.5 The VEGF knockout mice exhibited massive chon-
drocyte death at the center of the epiphysis at embryonic day
16.5 (E16.5), suggesting that VEGF may have a direct role in
chondrocyte survival.5 VEGF has also been shown to play an
important role in regulating cartilage resorption and blood
vessel invasion, because it is believed to be actively respon-
sible for hypertrophic cartilage neovascularization through a
paracrine release by hypertrophic chondrocytes, with invad-
ingendothelial cells as the target.6–8Alternatively, theblocking
of VEGF via the systemic administration of a soluble receptor
chimeric protein (Flt-(1-3)-IgG) led to a suppression of blood
vessel invasion into the growth plate, concomitant with
impaired trabecular bone formation and expansion of the
hypertrophic chondrocyte zone.9 Capillary invasion and res-
toration of the bone growth plate architecture followed re-
moval of the anti-VEGF treatment. Taken together, these
findings indicate that VEGF is an essential coordinator of
chondrocyte death, chondroclast function, extracellular ma-
trix remodeling, and angiogenesis in the growth plate.9
VEGF also plays an important role in osteoblast biology. It
has been shown to induce migration, parathyroid hormone–
dependent accumulation and an increase in alkaline phos-
phatase (ALP) in osteoblasts. It is also thought to be an
important regulator of osteoblastic differentiation.10 Osteo-
blasts express VEGF receptor (VEGFR)-1 and 2 and neuro-
pilin (Nrp),11,12 and treatment of mice with a soluble,
neutralizing VEGFR decreased angiogenesis, bone forma-
tion, and callus mineralization in femoral fractures. In other
studies, blocking the function of VEGF with an antiangio-
genic agent (TNP-470) or when mice lacked the expression of
VEGF isoforms VEGF164 and VEGF188 impaired every step
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of endochondral bone formation and led to decreased an-
giogenesis and bone formation.13,14 Conversely, exogenous
VEGF enhanced blood vessel formation, ossification, and
new bone (callus) maturation in mouse femur fractures and
promoted bony bridging of a rabbit radius segmental gap
defect.12 Therefore, VEGF is an essential growth factor in
regulating the process of endochondral bone formation.
Several studies have applied VEGF in combination with
bone morphogenetic protein 4 (BMP4) to promote endo-
chondral bone formation. One study demonstrated that a
poly- (lactic-co-glycolic acid) scaffold containing combina-
tions of human bone marrow stromal cells and condensed
plasmid DNA encoding BMP4 or VEGF elicited greater
bone formation than any single factor alone or combination of
the other two factors.15 Our group has previously reported the
synergistic effect of VEGF and BMPs on promoting endo-
chondral bone formation by using muscle-derived stem cells
(MDSCs).16,17 In these studies, the MDSCs were retrovirally
transduced to express VEGF, BMP2, or BMP4; the resulting
cell populations were then combined at different ratios, based
on the number of BMP-expressing cells to VEGF-expressing
cells, and implanted into a gluteofemoral (GF) skeletal muscle
pocket of mice. A ratio of 5:1, which corresponded to the im-
plantation of five BMP4-expressing MDSCs for every VEGF-
expressing MDSC, was found to promote bone formation
better than the implantation of cells expressing BMP4 only.16
Although these studies were informative as to the importance
of VEGF in promoting endochondral bone formation, they did
not take into account the effect that cellular proliferation may
have had on the in vivo ratio of BMP4 to VEGF. Once the cells
expressing BMP4 or VEGF were implanted into the skeletal
muscle pocket, they may have proliferated at different rates,
and this would change the initial pre-implantation ratio of
BMP4 to VEGF.
To determine how the stable ratio of BMP4 to VEGF in vivo
might affect VEGF’s promoting role in endochondral bone
formation induced by cell-based gene therapy, we used a cell-
mediated double-gene co-expressing approach that kept the
ratio of BMP4 to VEGF constant over time. To do so, two
easily accessible mouse cell lines were used in the present
study. C2C12 cells (mouse myoblasts) and NIH=3T3 cells
(mouse fibroblasts) were transduced with a retroBMP4 virus
only or a combination of retroBMP4 and retroVEGF viruses,
and their osteogenic potential was compared at different time
points in vitro and postimplantation in vivo.
Materials and Methods
Cell culture
C2C12 cells and NIH=3T3 cells were purchased from
the American Type Culture Collection (Manassas, VA). All
cells were cultured in Dulbecco’s Modified Eagle’s Medium
(DMEM) supplemented with 10% Fetal Bovine Serum (FBS)
and 1% penicillin-streptomycin and incubated at 378C in hu-
midified air mixed with 5% carbon dioxide (CO2).
Construction of retroviral vectors expressing lacZ,
human BMP4, and VEGF
A retrovirus carrying genes for the nuclear localizing signal
and b-galactosidase was produced from a stably transfected
cell line known as Tel-6.18 RetroBMP4 is an MFG-based ret-
roviral vector containing the human BMP4 gene plasmid,
pCLBMP4. Retroviral vectors expressing human VEGF were
constructed by cloning the VEGF165cDNA (InvivoGen, San
Diego, CA) into pCLX, resulting in pCLVEGF.16 The retro-
viruses expressing BMP4 and VEGF were termed retroBMP4
and retroVEGF, respectively.
Cell transduction using the same concentration
of retroBMP4 and retroVEGF
C2C12 cells were seeded at a density of 1.5105 cells per
75-cm2 flask and were grown to 50% confluence. On the day
of transduction, cells were washed twice with sterile Phos-
phate Buffered Saline (PBS) and incubated with a mixture of
10mL of retroBMP4 viral suspension (1106–5106 colony
forming units (cfu)=mL), 10mL of DMEM supplemented
with 10% FBS, and hexadimethrine bromide (8 mg=mL).
Transduction was carried out at 378C in 5% CO2 for a total of
48 h, and the viral suspension was replaced at 16 h and 32 h.
The culture medium from C2C12 cells transduced with
retroBMP4 (C2C12-B) was collected after 48 h, centrifuged
for 5min at 2000 rpm at 48C to remove cellular debris, and
used to perform a BMP4 bioassay.
Cells were then transduced a second time with retroVEGF.
The same protocol as described above was used for this sec-
ond transduction. C2C12-B cells were cultured in retroVEGF
viral suspension (1106–5106 cfu=mL) for a total of 48 h,
with medium being changed every 16 h, as described above.
The culture medium from C212-B cells transduced with
retroVEGF (C2C12-B-V) was collected after 48 h, centrifuged
for 5min at 2000 rpm at 48C, and used to perform a VEGF
assay (Enzyme-Linked ImmunoSorbent Assay (ELISA)).
C2C12 cells were also transduced solely with a retroVEGF to
create the C2C12-V cells, following the same protocols de-
tailed above. NIH=3T3 cells were transduced and analyzed
using the same methods as the C2C12 cells. NIH=3T3 cells
transduced with retroBMP4 were termed 3T3-B, and these
3T3-B cells were then transduced with retroVEGF and named
3T3-B-V. Exclusively for the C2C12-B-V cell group, they were
transduced a third time with a retroLacZ virus according to
the protocol described above, which yielded the C2C12-B-V-L
cell group for the in vivo experiments.
Cell transduction with retroBMP4 and various
concentrations of retroVEGF
RetroVEGF suspension used in the previous section was
diluted 0, 5, and 50-fold, and used to transduce C2C12-B and
3T3-B cells according to the protocol described above. This
resulted in the following cell groups: C2C12-B-V50 (retroVEGF
diluted by a factor of 50), C2C12-B-V5 (retroVEGF diluted by a
factor of 5), and C2C12-B-V0 (undiluted retroVEGF). For the
3T3 cells, the new populations were also named according to
the retroVEGF dilution (3T3-B-V50, 3T3-B-V5, 3T3-B-V0).
BMP4 bioassay and quantification of VEGF production
using untransduced and transduced cells
A previously described BMP4 bioassay19 was used to de-
termine the level of bioactive BMP4 secreted by the trans-
duced cells. ELISA kits (Human VEGF ELISA Kit, R&D
Systems,Minneapolis, MN)were used to quantify the amount
of VEGF being secreted by the transduced cells.
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Cell proliferation assay
C2C12, C2C12-V, C2C12-B, and C2C12-B-V were assayed
for their cell proliferation rate in cell culture medium (DMEM
with 1% FBS). A 200-mL cell suspension of C2C12, C2C12-V,
C2C12-B, and C2C12-B-V cells was plated in triplicate on the
96-well plates (6.25103 cells=well). Cells were cultured in the
96-well plates for 2 days, after which 20 mL of CellTiter 96
AQUEOUS One Reagent (Promega,Madison,WI) was added to
each well. The plate was subsequently incubated in 5%CO2 at
378C for 2.5 h, and the absorbance was read at 490 nm using a
96-well plate reader. NIH=3T3 cell groups were investigated
in the same manner.
Pellet culture
Mineralization assay. The four transduced cell groups
(C2C12-B, C2C12-B-V, 3T3-B, 3T3-B-V) were cultured as pel-
lets to evaluate calcification in vitro. Briefly, 2.5105 cells were
centrifuged at 500 g in 15-mL polypropylene conical tubes,
and the resulting pellets were cultured for up to 4 weeks in
osteogenic medium (DMEM supplemented with 10%FBS, 1%
penicillin=streptomycin, 107M dexamethasone, 50mg=mL
ascorbic-acid-2-phosphate, and 102M b-glycerophosphate),
which was changed every 2 to 3 days. Samples were har-
vested on days 7, 14, 21, and 28 and embedded in paraffin
block. Pellet sections were stained with von Kossa=eosin
staining.
Chondrogenesis assay. 3T3-B and 3T3-B-V cells were
made into pellets as described above and cultured in chon-
drogenic medium (Lonza Group Ltd, Basel, Switzerland).
Samples were harvested on days 21 and 28 and embedded in
a paraffin block, and the pellet sections were stained with
Alcian blue=nuclear fast red.
Terminal deoxynucleotidyl transferase 20-deoxyuridine
50-triphosphate nick end labeling assay. The deparaffinized
chondrogenic pellet sections of 3T3-B and 3T3-B-V were di-
gested with proteinase K following the protocol provided by
the manufacturer (ApopTag Plus Peroxidase In Situ Apop-
tosis Detection Kit, Chemicon, Temecula, CA). The terminal
deoxynucleotidyl transferase 20-deoxyuridine 50-triphosphate
nick end labeling (TUNEL) stain was visualized using a
substrate system that stained purple (VIP Substrate Kit, Vec-
tor Laboratories, Burlingame, CA). After staining, the sec-
tions were examined under the microscope, and positive cells
found in the center area of the pellets were quantified.
Western blot analysis for the expression of Nrp-1 and
hypoxia-inducible factor 1 subunit alpha in 3T3 cells
3T3, 3T3-B, and 3T3-B-V cell lysates in sample buffer
(2-mercaptoethanol and Laemmli sample buffer, Bio-Rad
Laboratories, Hercules, CA) were collected, incubated in
boiling water for 5min, and centrifuged, and the supernatant
was stored at 48C. Samples were resolved on 10% sodium
dodecyl sulfate–polyacrylamide gels and then transferred to
pure nitrocellulose membranes (Bio-Rad Laboratories). The
membranes were treated as detailed in the manufacturer’s
protocol (Vectastain ABC-AmP, Vector Laboratories). Anti-
nrp-1 (PC343T, 1:100, Calbiochem, San Diego, CA) and
hypoxia-inducible factor 1 subunit alpha (HIF-1a) antibody
(38-9800, 1:100, Zymed, South San Francisco, CA) were used
for this experiment.
Viability assay of 3T3, 3T3-B, and 3T3-B-V cells
Three groups of 3T3 cells were plated in triplicate on the
96-well plates (1.25104 cells=well). Cells were cultured in
DMEM supplemented with 1% FBS and 100mm or 400 mm
hydrogen peroxide (H2O2) in the 96-well plates for 2 days.
After 2 days, 20mL of CellTiter 96 AQUEOUS One Reagent
(Promega, Madison, WI) was added to each well; the plate
was subsequently incubated for 2.5 h, and the absorbance
was read at 490 nm using a 96-well plate reader.
Preparation of gelatin sponge implants
A 100-mL cell suspension containing 2105 cells (for each
group of C2C12 and NIH=3T3 cells) was seeded on the
surface of a 6- 6-mm piece of sterile gelatin sponge (Gel-
foam; Pharmacia & Upjohn Co, Kalamazoo, MI). After the
Gelfoam absorbed the cell suspension, 3mL of DMEM sup-
plemented with 10% FBS was added to each well, and the
implants were incubated overnight. The following day, the
seeded Gelfoam scaffolds were implanted into the skeletal
muscle pocket of the gluteofemoral muscles of severe com-
bined immunodeficient mice. The mice were sacrificed at 7,
10, 14, 20, 27, and 35 days after cell implantation. All animal
experiments were conducted with the approval of the Ani-
mal Research and Care Committee of the Children’s Hospital
of Pittsburgh.
Radiographic and histological analyses
Ectopic bone formation was monitored using X-ray ex-
amination of the mice at day 28 postimplantation (Model
MX-20, Faxitron X-ray Corporation, Lincolnshire, IL). To
visualize mineralized matrix deposition and bone volume
analysis in vitro and in vivo, a micro computed tomography
(microCT) imaging system (vivaCT40; Scanco Medical, Bas-
sersdorf, Switzerland) was used to scan all of the osteogenic
pellets and in vivo samples. Tissue samples were obtained at
sacrifice, treated with CRYO-GEL Embedding Medium
(Cancer Diagnostics, Inc, Birmingham, MI), rapidly frozen in
liquid nitrogen precooled 2-methylbutane (Sigma, St. Louis,
MO), and stored at 808C. Frozen sections were stained as
detailed below.
Alcian blue=eosin staining
A 1% Alcian blue solution was made with 3% acetic acid.
Frozen sections were fixed in 10% neutral buffered forma-
lin for 10min and rinsed in distilled water. Slides were placed
in 3% acetic acid for 3min and then transferred into the
Alcian blue solution for 30min, after which they were rinsed
in running tap water for 1min and counterstained with eosin.
Von Kossa=eosin staining
Frozen sectionswere fixed in 10%neutral buffered formalin
for 10min, followed by 3 rinses in distilled water. The slides
were then stained in 2% silver nitrate solution in the dark
for 15min, rinsed three times in distilled water, and exposed
to light for 15 to 30min until appropriate stain development
was achieved, after which the sections were counterstained
with eosin.
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Human BMP4 and VEGF immunostaining
and hematoxylin staining
The sections were processed for human BMP4 immuno-
staining as suggested in the manufacturer’s protocol (Vec-
tastain Elite ABC kit, Dab Substrate Kit for Peroxidase;
Vector Laboratories). Human BMP4 antibody (1:100 dilution,
AF757; R&D Systems) and human VEGF antibody (1:100
dilution, AB-293NA; R&D Systems) were used for the
immunostaining. These sections were counterstained with
hematoxylin.
Quantitative measurement of newly formed
cartilage, bone, and the density of human BMP4
and VEGF staining
Full views of histological sections were obtained using
microscopy, and various measurements were obtained with
Northern Eclipse imaging software (Empix Imaging Inc.,
Mississauga, Canada). A measurement of the cartilage for-
mation was obtained by analyzing the blue area, which in-
dicated a positive reaction with Alcian blue. A measurement
of bone formation was obtained by analyzing the black area,
which indicated a positive reaction to von Kossa staining. A
measurement of the density of the human BMP4 and VEGF
staining was obtained using Northern Eclipse software to
analyze the level of brown color, which indicated the positive
expression of human BMP4 and VEGF (i.e., a positive result
after treatment with the Dab Substrate Kit for Peroxidase).
Immunostaining for lacZ and CD31 in tissue
sections of C2C12-B-V-L cells
Tissue sections were fixed in aectone:methanol (1:1) at
room temperature for 5min and then blocked with 7.5%
donkey serum and 7.5% goat serum for 30min. CD31 anti-
body (1:200 dilution, BD 553370) and lacZ antibody (1:200
dilution, Abcam) were added to the tissue sections for 3 h at
room temperature. Sections were washed in PBS three times
for 5min. Secondary antibodies, goat anti-rat 555 (1:300 di-
lution) and donkey anti-rat 488 (1:300 dilution), were added
to sections for 1 h at-room temperature. 40,6-diamidino-
2-phenylindole (1:1000 dilution) was added to sections for
5min. Sections were washed in PBS three times and examined
under a fluorescence microscope.
FIG. 1. Growth factors secretion and proliferation rate of genetically engineered cells. (A) Amount of recombinant human
bone morphogenetic protein 4 (rhBMP4) secreted by C2C12-B and 3T3-B into the culture medium. (B) Amount of recom-
binant human vascular endothelial growth factor (rhVEGF) secreted by C2C12-B-V and 3T3-B-V into the culture medium. (C,
D) Proliferation of the different populations of (C) C2C12 and (D) 3T3 cells before and after transduction with retroVEGF,
retroBMP4, or both. **P< 0.01 indicates a significant difference between (C) C2C12-B and all other C2C12 groups, and
between (D) the 3T3 groups.
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Statistical analysis
Data are reported as means standard deviations and
analyzed using two-way analysis of variance with Tukey’s
post hoc test.
Results
Expression of human BMP4 and VEGF
from transduced C2C12 and NIH=3T3 cells
The two types of cells used in this study were both able to
synthesize, process, and secrete active recombinant human
(rh) BMP4 after transduction with retroBMP4. The amount
of secreted rhBMP4 reached 105 10 ng=million cells per 24 h
in C2C12 cells and 98 5 ng=million cells per 24 h in NIH=
3T3 cells (Fig. 1A). The two types of BMP4-expressing cells
transduced with retroVEGF secreted rhVEGF at a level of
152 20 ng=million cells per 24 h in C2C12 cells and 128
12 ng=million cells per 24 h inNIH=3T3 cells (Fig. 1B). In terms
of b-galactosidase gene (LacZ) transduction efficiency, 75% of
the C2C12-B-V cells were LacZ positive.
Differential effects of BMP4 and VEGF on the
proliferation rate of C2C12 and NIH=3T3 cells
C2C12-V showed a proliferation potential similar to that of
the non-transduced C2C12 cells (Fig. 1C). When the C2C12
cells were transduced with retroBMP4 (C2C12-B), their
FIG. 2. Mineralization potential and chondrogenic differentiation of C2C12 and NIH=3T3 in vitro. With von Kossa=eosin
staining, the calcified tissue is stained black and surrounding tissue is stained red. (A) C2C12-B-V cell pellets displayed less
mineralization than the C2C12-B cells at different time points when cultured in osteogenic medium (scale bar represents
250 mm). (B) Micro computed tomography analysis showed that C2C12-B pellets had more mineralized tissue than C2C12-B-V
pellets at days 7 and 14 (*p< 0.05). (C) The 3T3-B-V cell pellets also showed less mineralization than 3T3-B cells (scale bar
represents 250mm). (D) With Alcian blue staining, cells in the 3T3-B-V group showedmore cells with normal morphology than
the 3T3-B group (scale bar represents 50mm). (E) Western blot analysis revealed a differential expression of neuropilin-1 (Nrp1)
and hypoxia-inducible factor 1 subunit alpha (HIF-1a) in three 3T3 cell groups. (F) Terminal deoxynucleotidyl transferase 20-
deoxyuridine 50-triphosphate nick end labeling staining of chondrogenic pellets showed less apoptosis in the 3T3-B-V pellets
than the 3T3-B pellets at day 28 (*p< 0.05), whereas no difference was observed at day 21. (G). Oxidative stress analysis showed
that 3T3-B-V cells displayed better survival than 3T3-B cells when cultured with 100 mM and 400mM of hydrogen peroxide
(*p< 0.05).
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proliferation potential was significantly greater than that of
the C2C12 and C2C12-V cells ( p< 0.01) (Fig. 1C). However,
C2C12-B-V cells displayed significantly poorer proliferation
potential than the C2C12-B cells ( p< 0.01) (Fig. 1C).
3T3 cells and 3T3-V cells displayed similar proliferation
rates (Fig. 1D). 3T3-B demonstrated a significantly greater
proliferation rate than the 3T3 and 3T3-V cell groups
( p< 0.01) (Fig. 1D). Transducing these cells to express BMP4
andVEGF (3T3-B-V) led to a significantly greater proliferation
rate than that of all other 3T3 cell groups ( p< 0.01) (Fig. 1D).
Pellet culture
In the in vitro mineralization assay, C2C12-B and 3T3-B
cell pellets directly calcified without going through a chon-
drogenic phase when cultured in the osteogenic medium.
The C2C12-B-V and 3T3-B-V cell groups showed less calci-
fication than the corresponding C2C12-B and 3T3-B cell
groups at different time points (days 7, 14, 21, and 28) (Fig.
2A, C). MicroCT analysis showed that C2C12-B-V pellets
displayed significantly less calcified tissue than C2C12-B cell
pellets at days 7 and 14 of culture ( p< 0.05) (Fig. 2B). Results
of Alcian blue staining showed that the 3T3-B-V cells ex-
hibited more cells with normal morphology in the center of
the pellet than was seen with the 3T3-B cells (Fig. 2D).
Western blot analysis showed that the 3T3-B and 3T3-B-V
cells expressed similar levels of Nrp-1 and HIF-1a and that
both expressed higher levels than the nontransduced 3T3
cells (Fig. 2E). TUNEL staining revealed that pellets made
with 3T3-B-V cells had significantly less apoptotic cells than
3T3-B pellets at day 28 of culture (p< 0.05) (Fig. 2F).
Survival analysis of different groups of 3T3 cells
3T3-B-V cells showed significantly higher resistance to
oxidative stress than 3T3-B cells when cultured in H2O2-
supplemented DMEM at different concentrations (100mM
and 400 mM) ( p< 0.05) (Fig. 2G).
Differential endochondral bone formation displayed
by two types of cells transduced with retroBMP4
or a combination of retroBMP4 and retroVEGF
C2C12-B cells displayed normal cartilage formation. In the
C2C12-B-V group, no cartilage was found at any of the time
points tested, yet irregular empty channels were observed
(Fig. 3A, C). Although the cartilaginous phase of endochon-
dral bone formation seen with 3T3-B and 3T3-B-V cells was
FIG. 3. Characterization of
the cartilaginous phase during
endochondral bone formation.
Alcian blue=eosin staining
revealed cartilage tissue, as
evidenced by the blue color;
the surrounding soft tissue is
seen as red. (A, C) Cartilage
tissue in C2C12-B started to
form at day 7, lasted 3 to 7
days, and was resorbed by
day 14. C2C12-B-V cells did
not have any indication of
cartilage formation at any
time points examined. This
was also confirmed via the
quantification of the cartilage
area (in pixels) in the three
groups (**p< 0.01 at days 7
and 10). (B, D) The two 3T3
cell groups showed a similar
pattern of cartilage formation
at the early time points (days
14–20). At days 27 and 35, the
3T3-B-V cell group demon-
strated significantly more
cartilage formation than the
3T3-B cell groups. The quan-
tification of cartilage area (in
pixels) in the three cell groups
further confirms this
(**p< 0.01 at days 27 and 35)
(scale bars represent 100mm).
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similar at early time points, the 3T3-B-V cells displayed a sig-
nificantly greater cartilage area at 27 and 35 days post im-
plantation (Fig. 3B, D).
In the case of bone formation, the C2C12-B cell group
showed normal bone production (Fig. 4A) (Supplemental
Fig. 1, available online at www.liebertonline.com=ten). Im-
plantation of C2C12-B-V cells demonstrated no bone forma-
tion at any time points tested, resulting in hemangioma-like
structure (Fig. 4A). Among the 3T3 cell groups, the 3T3-B-V
cell group displayed a smaller bone area than the 3T3-B cell
group at early time points (days 10–14) and almost no bone
formation at the later time points (days 27 and 35) (Fig. 4B, D).
These observations were also verified using X-ray examina-
tion at day 28 postimplantation (Fig. 4E, F). No synergistic
effect of VEGF on BMP4-induced bone formation was ob-
served with our primary skeletal muscle cells co-expressing
BMP4 and VEGF (Supplemental Fig. 2, available online at
www.liebertonline.com=ten).
FIG. 4. Characterization of
the osteogenic potential of the
various cell groups in vivo.
With von Kossa=eosin stain-
ing, the calcified tissue is
stained black, and the sur-
rounding soft tissue is stained
red. (A, C) C2C12-B cells
demonstrated bone tissue for-
mation. C2C12-B-V cells did
not generate any bone tissue
but merely produced a lattice
of irregular channels within
the soft tissues (scale bars
represent 100mm). The bone
area (in pixels) of C2C12-B
was significantly larger than
that of C2C12-B-V at different
time points (**p< 0.01 at days
10–35). (B, D) 3T3-B cells ex-
hibited a normal pattern of
bone formation, whereas 3T3-
B-V cells showed poorer bone
formation with time (scale
bars represent 100mm). The
bone area (in pixels) seen with
the 3T3-B cell group was sig-
nificantly larger than that of
the 3T3-B-V cell group
(**p< 0.01 at days 20–35). (E)
X-ray analysis at day 28 after
implantation showed that the
C2C12-B cell group displayed
an area of high density in the
gluteofemoral muscle pocket
of severe combined immuno-
deficient mice, whereas the
C2C12-B-V cells showed no
radio-opaque area in the
muscle pocket. (F) X-ray
analysis at day 28 after im-
plantation showed that 3T3-B
cells produced an area of high
density in the muscle pocket,
whereas 3T3-B-V cells ex-
hibited no radio-opaque area
in the muscle pocket.
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FIG. 5. Expression of human bone morphogenetic protein (BMP)4 and vascular endothelial growth factor (VEGF) in vivo.
(A, B) Staining of the tissue obtained from the C2C12-B-V group at different time points postimplantation showed that
human VEGF and BMP4 expression levels increased with time in vivo. (C, D) 3T3-B-V cells also showed greater human VEGF
and BMP4 expression level with time. (E) Gross appearance of the in vivo tissue sample from the C2C12-B-V group that was
stained with hematoxylin and eosin showed a hemangioma-like structure that stained positive for human BMP4 and VEGF
(positive¼ brown color) (scale bar represents 3000 mm). (F) The tissue section stained for CD31 and LacZ immunofluorescence
(scale bar represents 100mm) revealed that most cells in the tissue section are CD31 positive (green) and with only a cell
positive for both LacZ (red nuclei) and CD31 (green) (arrowhead) (scale bar represents 25 mm) under a higher magnification.
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Quantitative measurement of human BMP4
and VEGF immunostaining
Human BMP4 and VEGF immunostaining results of
in vivo samples (implanted C2C12-B-V and 3T3-B-V cells) at
different time points revealed that BMP4 and VEGF expres-
sion levels increased with time (Fig. 5A-D).
Results of histological and immunochemical staining
Hematoxylin and eosin staining revealed that C2C12-B-V
cells induce a hemangioma-like structure. When these tissues
were immunostained with human BMP4 or human VEGF,
both proteins were expressed in the tissue sections (Fig. 5E).
Although most of the cells in the hemangioma-like structures
stained positive with CD31, double staining with lacZ and
CD31 indicated that most of the CD31-positive cells were
negative for lacZ staining (Fig. 5F).
Co-expression of BMP4 and VEGF at different ratios
influence the mineralization potential
C2C12-B and 3T3-B cells secreted different amounts of
VEGF after transduction with various concentrations of
retroVEGF (V50, V5, and V0; Fig 6A, B). The level of secreted
VEGF of C2C12-B-V50, C2C12-B-V5, and C2C12-B-V0
reached 16 5 ng=million cells per 24h, 60 8 ng=million cells
per 24h, and 440 24ng=million cells per 24 h, respectively.
The secreted VEGF level of 3T3-B-V50, 3T3-B-V5, and 3T3-
B-V0 reached 4 1 ng=million cells per 24 h, 30 3 ng=million
cells per 24h, and 150 12ng=million cells per 24h, respec-
tively. When these various populations of C2C12 and 3T3
cells were implanted in vivo, and the mineralized tissue was
quantified using microCT, less mineralized potential was ob-
served with greater concentration of secreted VEGF. The cells
transduced with nondiluted retroVEGF (C2C12-B-V0 and
3T3-B-V0) displayed the lowest amount of mineralized tissue
volume,whereas cells transducedwith a retroVEGFdiluted by
a factor of 5 and 50 showed significantly greater mineralized
tissue volume than the V0 group (Fig. 6C-F).
Discussion
Previous studies have shown that VEGF has a promoting
effect on endochondral bone formation induced by BMP4,16,17
but these studies have relied on the separate delivery of
BMP4 and VEGF by transducing cells to express BMP4 or
VEGF and then implanting them at certain ratios. Because of
this limitation, the possibility cannot be excluded that the
BMP4-transduced cells may proliferate at a different rate than
the VEGF-transduced cells and consequently influence the
initial established ratio of BMP4 to VEGF several days post-
implantation. The current study confirmed these differences
in proliferation rate by comparing the proliferation rates of
untransduced cells with those of cells transduced to express
VEGF, BMP4, or both. In the case of C2C12 and NIH=3T3
cells, cells transduced with a retroBMP4 had a greater pro-
liferation rate than the cells expressing VEGF alone. For this
reason, it remains unclear how a ratio of BMP4 to VEGF
that remains constant in vivo might affect VEGF’s promot-
ing role in endochondral bone formation. In this study, we
aimed to keep the BMP4:VEGF ratio constant by transduc-
ing C2C12 and NIH=3T3 to simultaneously express BMP4
and VEGF. Hence, regardless of the proliferation rate dif-
ferences, the ratio of BMP4 to VEGF would remain constant
over time.
C2C12 cells transduced to express BMP4 have previously
been shown to form bone when implanted into the intra-
muscular pocket of mice.20 In the present study, when C2C12-
B-V cells were analyzed for their ability to form mineralized
tissue in vitro, it was determined that the co-expression of
VEGF inhibited the calcification seen with BMP4-expressing
C2C12 cells cultured as pellets in osteogenic medium. This
lack of mineralization in vitro might explain the subsequent
lack of bone formation in vivowith the C2C12-B-V cell group,
although it is not thought to be the sole explanation, because
cell pellets madewith C2C12-B-V cells still displayed a certain
amount of calcification at days 21 and 28 when cultured in
osteogenic medium in vitro. Another possibility is that the
implanted C2C12-B-V cells may have differentiated into en-
dothelial cells instead of osteoblasts under the synergistic ef-
fect of BMP4 and VEGF, although when we followed the fate
of the donor cells using LacZ staining, we observed that few
donor cells co-expressed the endothelial cell marker CD31,
suggesting that the C2C12-B-V cells did not readily differen-
tiate into endothelial cells. The findings observed with C2C12
cells transduced to express BMP4 and VEGF are in accor-
dance with the results from another study that demonstrated
that BMP2 could induce vascularization, enhance angio-
genesis, and result in vascularized tumor formation.21 We
therefore postulate that implanted C2C12-B-V cells continu-
ously overexpressed VEGF and recruited host cells in vivo that
consequently participated in the in vivo formation of the
hemangioma-like structures observed.
Unlike the findings obtained with C2C12-B-V cells, im-
plantation of 3T3-B-V cells led to the formation of tissues
filled with a prolonged and more-persistent cartilaginous
phase. These findings are in accordance with our previous
study, which reported that NIH=3T3 cells have a distinctly
greater potential for producing cartilage, both in vitro and in
vivo, when treated with BMP4.20 The 3T3-B-V cell group
produced more cartilage and less bony tissue than the 3T3-B
cell group at the different time points (days 27 and 35) after
in vivo implantation. The mechanism was believed to be dif-
ferent from that of C2C12-B-V cells. The 3T3-B-V cells dis-
played a greater proliferation potential than the 3T3-B cells,
which demonstrated the promoting effect of BMP4 and VEGF
on the proliferation of NIH=3T3 cells. In addition, 3T3-B-V
cell pellets cultured in chondrogenic medium showed less cell
apoptosis than the pellets made with 3T3-B cells. Western blot
analysis showed that the co-transduced NIH=3T3 with ret-
roBMP4 and retroVEGF upregulated HIF-1a and the VEGFR
Nrp-1. It has been reported that HIF-1a regulates the tran-
scription of a broad range of genes that are involved in a
variety of processes such as glucose metabolism, angiogene-
sis, and cell survival.22–25 Nrp-1 is a co-receptor membrane-
bound to a tyrosine kinase receptor for VEGF that plays a role
in angiogenesis, axon guidance, cell survival, migration, and
tumor invasion.11 Our results also indicated that 3T3-B-V
cells had a better cell survival rate than 3T3-B and 3T3 cells
when they were exposed to oxidative stress. Hence, the
greater proliferation and survival potential displayed by 3T3-
B-V cells than by 3T3-B cells might explain, at least in part,
the observation that more cartilage formation was found in
the 3T3-B-V cell group in vivo. With regard to the poorer bone
production seen in this group than in the 3T3-B group, the
SYNERGISTIC EFFECT OF VEGF ON BMP4–INDUCED BONE FORMATION IS DOSE DEPENDENT 2131
explanation is thought to be that a constant high level of
VEGF expression could inhibit the calcification of 3T3-B-V
cells in vivo, which was supported by the observation that cell
pellets made with 3T3-B-V cells have less calcification than
those made with 3T3-B cells at different time points (days 7,
14, 21, and 28) when cultured in osteogenic medium in vitro.
Transducing C2C12-B and 3T3-B cells with different
concentrations of retroVEGF further confirmed that co-
expression of VEGF and BMP4 lead to impaired mineralized
tissue formation, especially with high doses of VEGF. Al-
though diluting the retroVEGF by a factor of 5 still impaired
bone formation, the dilution by a factor of 50 eliminates the
detrimental effect and consequently induces mineralized tis-
sue formation similar to that of the BMP4-only transduced
cells. Therefore, these results suggest that co-expression of
BMP4 and VEGF in our experimental setting impaired ectopic
endochondral bone formation, especially when the ratio of
VEGF to BMP4 was high. However, if the ratio of VEGF to
BMP4 is kept low and constant, then the detrimental effect on
the ectopic bone formation is lost.
In summary, the present study demonstrated that
co-expression of VEGF and BMP4 influenced ectopic endo-
chondral bone formation and provided additional knowl-
edge as to the importance of the BMP:VEGF ratio for this
process. Although our results indicate that a high ratio of
VEGF to BMP4 led to a detrimental effect on bone formation,
we have also observed that, if the ratio of VEGF to BMP4 is
kept low and constant for a prolonged period of time, det-
rimental effect of VEGF on bone formation is lost. Therefore,
when developing cell-based gene therapies for tissue engi-
neering, it will be important to thoroughly investigate not
only the benefits of growth factors, but also their interaction,
their respective doses and timing of action, and finally their
effect on given cell types.
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